SmartPA Criteria Proposal

Drug/Drug Class:	Sympatholytic Agents PDL Edit
First Implementation Date:	January 5, 2017
Proposed Date:	September 17, 2020
Prepared For:	MO HealthNet
Prepared By:	MO HealthNet/Conduent
Criteria Status:	☒Existing Criteria ☐Revision of Existing Criteria ☐New Criteria

Executive Summary

Purpose: The MO HealthNet Pharmacy Program will implement a state-specific preferred drug list.

Why Issue Selected: The sympatholytic agents are indicated for various functions for example, treatment of hypertension, anxiety, panic disorder, post traumatic stress disorder and withdrawal symptoms from opioids. The oral, centrally-acting, alpha-2 adrenergic receptor agonists include clonidine and guanfacine. Methyldopa continues to be used to treat hypertension in pregnant women. A diuretic, usually hydrochlorothiazide or chlorthalidone may be combined with clonidine or methyldopa. The sympatholytics are typically part of a multiple antihypertensive drug regimen for participants who have not reached their target blood pressure. Clonidine is also available in a transdermal formulation for the treatment of hypertension.

Total program savings for the PDL classes will be regularly reviewed.

Program-Specific Information:

Preferred Agents	Non-Preferred Agents
• Catapres-TTS® Patch • Clonidine • Guanfacine • Methyldopa	• Catapres® Tabs • Clonidine Transdermal • Lucemyra® • Methyldopa/HCTZ

Type of Criteria:

☐ **Increased risk of ADE**	☒ **Preferred Drug List**
☒ **Appropriate Indications**	☐ **Clinical Edit**

Data Sources: ☐ **Only Administrative Databases** ☒ **Databases + Prescriber-Supplied**

Setting & Population

- Drug class for review: Sympatholytic Agents
- Age range: All appropriate MO HealthNet participants

© 2020 Conduent Business Services, LLC. All rights reserved. Conduent™ and Conduent Design™ are trademarks of Conduent Business Services, LLC in the United States and/or other countries.

Other company trademarks are also acknowledged.

Approval Criteria

- Failure to achieve desired therapeutic outcomes with trial on 3 or more preferred agents:
  - Documented trial period for preferred agents **OR**
  - Documented ADE/ADR to preferred agents
- For Lucemyra:
  - Documented diagnosis of opioid withdrawal **AND**
  - Documented trial period of clonidine oral OR patch

Denial Criteria

- Lack of adequate trial on required preferred agents
- Therapy will be denied if all approval criteria are not met

Required Documentation

Laboratory Results:	☐	Progress Notes:	☐
MedWatch Form:	☐	Other:	☐

Disposition of Edit

Denial: Exception Code "0160" (Preferred Drug List)
Rule Type: PDL

Default Approval Period

1 year

References

1. Evidence-Based Medicine and Fiscal Analysis: "Sympatholytic Antihypertensive Agents – Therapeutic Class Review", Conduent Business Services, L.L.C., Richmond, VA; July 2020.
2. Evidence-Based Medicine Analysis: "Sympatholytic Antihypertensives", UMKC-DIC; June 2020.
3. Lippincott, Williams, Wilkins. PDR Electronic Library, Montvale NJ; 2020.
4. USPDI, Micromedex; 2020.
5. Facts and Comparisons eAnswers (online); 2020 Clinical Drug Information, LLC.

© 2020 Conduent Business Services, LLC. All rights reserved. Conduent™ and Conduent Design™ are trademarks of Conduent Business Services, LLC in the United States and/or other countries.

Other company trademarks are also acknowledged.